K-numberK251934
Device nameqXR-Detect
ApplicantQure.Ai Technologies
Product codeMYN
Device classClass II
Decision dateJan 16, 2026
DecisionSubstantially Equivalent
Regulation892.2070
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

qXR-Detect is a computer-assisted detection (CADe) software device that analyzes chest radiographs and highlights suspicious regions of interest (ROIs) across six anatomical categories: lung, pleura, bone, mediastinum & hila & heart, hardware, and other. It is intended for use as a concurrent reading aid by ER physicians, family medicine practitioners, and radiologists to support (not replace) clinical decision-making in adult patients.

Technological characteristics

qXR-Detect uses deep learning (CNN-based architecture) to analyze DICOM chest X-ray images, similar to the predicate device Chest CAD. Both devices employ machine learning for ROI detection and localization, support PACS integration and cloud or on-premises deployment, and are HIPAA-compliant. qXR-Detect categorizes findings into six anatomical categories versus the predicate's seven categories, but both share the same fundamental CADe software approach and intended users.

Test standards cited

ISO 13485:2016 (quality management systems) and IEC 62304:2006+A1:2015 (medical device software lifecycle) were referenced as regulatory standards. Testing included unit, integration, regression, and user acceptance testing; non-clinical standalone performance testing with 301 chest X-ray samples; and a clinical multireader multicase study with 18 readers evaluating detection and localization using weighted alternative free-response receiver operating characteristic (wAFROC) metrics.

Substantial equivalence argument

qXR-Detect is substantially equivalent to Chest CAD (K210666) because both are CADe software devices that analyze chest radiographs using deep learning to identify and localize suspicious ROIs for concurrent clinical use in adults. The devices share identical regulatory classification (Class II, 21 CFR 892.2070, product code MYN), similar intended purpose, overlapping technological characteristics, and comparable performance metrics. Clinical testing demonstrated significant improvement in reader performance when aided by qXR-Detect, with wAFROC improving from 0.6894 unaided to 0.7505 aided (p<0.001), confirming safety and effectiveness without raising new safety or effectiveness questions.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →